newsfilter
← Latest News
GlobeNewswire·

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

DERMFBIO
  • Total revenues for FY2025 were $61.9 million, a 10% increase from $56.1 million in FY2024.
  • Emrosi™ generated $14.7 million in net revenues following its launch in early April 2025.
  • Approximately 53,000 prescriptions for Emrosi™ were filled during FY2025.
  • Payer access for Emrosi™ now covers over 100 million U.S. commercial lives.
  • Gross margin improved to 66.2% in FY2025 from 62.8% in FY2024, driven by higher-margin products including Emrosi™.
  • Selling, general, administrative expenses increased 10% to $44.4 million due to operational activities related to the Emrosi™ launch.
  • Net loss for FY2025 was $11.4 million ($0.47 per share), an improvement from $14.7 million ($0.72 per share) in FY2024.
  • Adjusted EBITDA for FY2025 was $2.9 million ($0.12 per share basic), compared to $0.8 million ($0.04 per share basic) in FY2024.
  • Cash and cash equivalents at year-end 2025 were approximately $24.1 million, up from $20.3 million in 2024.
  • Working capital increased to $29.4 million at December 31, 2025, from $13.0 million in 2024.
  • Revenue from Accutane® declined by $6.5 million in FY2025 due to competitive pressures.
  • Clinical trial data for Emrosi™ (DFD-29) published in JAMA Dermatology demonstrated efficacy, safety, and tolerability for rosacea.
  • Pooled analysis presented in October 2025 showed Emrosi™ had superior efficacy versus placebo and doxycycline.
  • Phase 1 trial results published in December 2025 indicated no detectable effects of Emrosi™ on skin, GI, or vaginal microflora.
  • Journey Medical announced a conference call for March 25, 2026, at 4:30 p.m. ET to discuss financial results.